Subscribe
0%
Illustration for: Isomorphic Labs raises $5B, its third round in 20 months. It still hasn't dosed a human — what to watch

Isomorphic Labs raises $5B, its third round in 20 months. It still hasn't dosed a human — what to watch

The Google DeepMind drug-discovery spinout closed a $5 billion Series C co-led by Greenoaks and Sequoia, taking outside funding to roughly $7.7 billion. It won't disclose a valuation, and the real test is whether its first AI-designed drug enters clinical trials by the end-of-2026 target Demis Hassabis set in January.

Listen to this article0:00 / 4:18

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, the company announced on November 17. Andreessen Horowitz joined as a new investor alongside several unnamed others, Alphabet invested again, and returning backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund all participated.

Why it matters: this is an enormous sum for a company that, as of Bloomberg's early-November reporting, had not yet tested any of its own drug candidates in people. It comes only six months after a $2.1 billion Series B, according to Reuters, and makes Isomorphic the clearest bet yet that AI models descended from AlphaFold can shorten the slow, failure-prone business of making medicines. The money is big; the evidence so far is preclinical.

The money, by the numbers

Round Date Amount Lead
First external round March 2025 ~$600 million —
Series B May 2026 $2.1 billion Thrive Capital
Series C November 2026 $5 billion Greenoaks, Sequoia (co-leads)
Total external funding ~$7.7 billion Tech Funding News calculation

Sources: Isomorphic, Reuters, Tech Funding News. Bloomberg had reported that the May round brought outside funding to $2.7 billion, per Dealroom, which is consistent with the ~$7.7 billion total.

Valuation: not disclosed. Isomorphic declined to give one, Reuters says. Bloomberg reported on November 4 that the company was in talks to raise about $5 billion at roughly $50 billion, up from an October report of at least $40 billion. Those figures came from people familiar with the talks and have not been confirmed by the company, so treat $50 billion as reported, not official.

What the money is for

Isomorphic's announcement is light on specifics. It says the round will accelerate its science and its in-house AI, scale IsoDDE (the Isomorphic Drug Design Engine) and advance its pipeline of AI-designed therapeutic candidates. It gives no breakdown of spending.

According to Reuters and Tech Funding News:

  • IsoDDE is meant to design molecules, predict their properties and refine candidates before chemists choose which ones to make and test. Hassabis describes its speed and precision as unprecedented; that is the company's claim, not an independent finding.
  • Pipeline: Isomorphic reports positive preclinical results in internal oncology and immunology programs and in partnered work, and Hassabis has told Bloomberg it has more than 20 programs under way.
  • Partners: Eli Lilly, Novartis and Johnson & Johnson. No deal values were given in the reports we read.

CEO Demis Hassabis said the round "enables us to accelerate our progress," per Reuters.

The deadline that matters

In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026, Tech Funding News notes. That is about six weeks away. Neither the announcement nor Reuters gives a start date; both describe the company as working to move its first candidates into the clinic.

Entering a Phase 1 trial would be a milestone, but a modest one: early trials mainly test safety, and many candidates that enter human testing never reach approval. Even a successful first trial would say little, on its own, about whether AI-designed molecules beat conventionally designed ones.

How it compares

The round dwarfs recent rivals' raises cited by Tech Funding News: Chai Discovery raised $400 million at a $3.8 billion valuation in July, Xaira Therapeutics launched in April 2024 with more than $1 billion, and Basecamp Research raised a $140 million Series C in September.

What to watch

  • A first-in-human announcement before year-end, and which program and partner it involves.
  • Whether a valuation is confirmed, in a filing or by an investor, versus the reported ~$50 billion.
  • Partner milestones from Lilly, Novartis or J&J, which would be the first outside validation of IsoDDE-designed molecules.
  • Who else raises next. A $5 billion round sets a new reference point for AI-bio startups; expect competitors to cite it.

Sources

  1. Isomorphic Labs — Isomorphic Labs announces Series C investment round isomorphiclabs.com
  2. Reuters via WSAU — AI drug developer Isomorphic raises $5 billion in Series C round wsau.com
  3. Tech Funding News — DeepMind spinout Isomorphic Labs lands $5B Series C to take AI-designed medicines into the clinic techfundingnews.com
  4. Dealroom — DeepMind spinout Isomorphic Labs in talks to raise about $5B at a $50B valuation dealroom.co

#Isomorphic Labs#Google DeepMind#Alphabet#Sequoia#Greenoaks#a16z#drug discovery#funding